Tubulis GmbH is focused on advancing the field of antibody-drug conjugates (ADCs) through a suite of proprietary technologies that enhance the efficacy and safety of cancer treatments. Their innovative approach includes the development of uniquely matched ADCs that leverage advanced conjugation, linker, and payload technologies. This enables the use of previously inaccessible targeting molecules and novel payloads, resulting in highly stable ADCs with superior biophysical properties. Their lead candidates, TUB-040 and TUB-030, are designed to target specific cancer-associated antigens, demonstrating effective tumor delivery and reduced off-target toxicities in preclinical models.

The company is currently conducting clinical trials for TUB-040, which targets NaPi2b in ovarian cancer and non-small cell lung cancer, and TUB-030, which targets the 5T4 antigen across various solid tumors. Both candidates have shown promising preclinical results, including durable anti-tumor responses and excellent safety profiles. Tubulis aims to translate its extensive research and development efforts into meaningful therapeutic benefits for patients, with a commitment to continuous innovation in ADC design to expand their therapeutic potential.

Germany

Tubulis® generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Our goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a new era and delivering better outcomes for patients. We will advance a range of conjugates, unlimited by indication, using our own discovery capabilities and by solving development challenges for partners with both antibody and chemical assets.

Tubulis GmbH

Company Details